Opportunities and Challenges for Fatty Acid Mimetics in Drug Discovery.
暂无分享,去创建一个
Ewgenij Proschak | Daniel Merk | Lena Kalinowsky | E. Proschak | D. Merk | Pascal Heitel | L. Kalinowsky | Pascal Heitel
[1] N. Sharma-Walia,et al. Lipoxins: nature’s way to resolve inflammation , 2015, Journal of inflammation research.
[2] M. Congreve,et al. A 'rule of three' for fragment-based lead discovery? , 2003, Drug discovery today.
[3] Amiram Goldblum,et al. Indexing molecules for their hERG liability. , 2013, European journal of medicinal chemistry.
[4] M. Raizman,et al. In vivo pharmacokinetics and in vitro pharmacodynamics of nepafenac, amfenac, ketorolac, and bromfenac , 2007, Journal of cataract and refractive surgery.
[5] J. Peters,et al. Pharmacological Promiscuity: Dependence on Compound Properties and Target Specificity in a Set of Recent Roche Compounds , 2009, ChemMedChem.
[6] Anna L. Blobaum,et al. Molecular Determinants for the Selective Inhibition of Cyclooxygenase-2 by Lumiracoxib* , 2007, Journal of Biological Chemistry.
[7] Nicholas A Meanwell,et al. Improving Drug Design: An Update on Recent Applications of Efficiency Metrics, Strategies for Replacing Problematic Elements, and Compounds in Nontraditional Drug Space. , 2016, Chemical research in toxicology.
[8] D. Im. Omega-3 fatty acids in anti-inflammation (pro-resolution) and GPCRs. , 2012, Progress in lipid research.
[9] Oliver Werz,et al. Multi-target approach for natural products in inflammation. , 2014, Drug discovery today.
[10] Shenghua Shi,et al. Scaffold-based discovery of indeglitazar, a PPAR pan-active anti-diabetic agent , 2009, Proceedings of the National Academy of Sciences.
[11] T. Willson,et al. Discovery of GSK1997132B a novel centrally penetrant benzimidazole PPARγ partial agonist. , 2011, Bioorganic & medicinal chemistry letters.
[12] T. Velkov,et al. Examination of the role of intestinal fatty acid-binding protein in drug absorption using a parallel artificial membrane permeability assay. , 2007, Chemistry & biology.
[13] G. Schneider,et al. Aminothiazole-featured pirinixic acid derivatives as dual 5-lipoxygenase and microsomal prostaglandin E2 synthase-1 inhibitors with improved potency and efficiency in vivo. , 2013, Journal of medicinal chemistry.
[14] G. Eichele,et al. International Union of Pharmacology. LX. Retinoic Acid Receptors , 2006, Pharmacological Reviews.
[15] Noeris K. Salam,et al. Novel PPAR‐gamma Agonists Identified from a Natural Product Library: A Virtual Screening, Induced‐Fit Docking and Biological Assay Study , 2007, Chemical biology & drug design.
[16] L. Altucci,et al. RAR and RXR modulation in cancer and metabolic disease , 2007, Nature Reviews Drug Discovery.
[17] Philippe Lehert,et al. Elafibranor, an Agonist of the Peroxisome Proliferator-Activated Receptor-α and -δ, Induces Resolution of Nonalcoholic Steatohepatitis Without Fibrosis Worsening. , 2016, Gastroenterology.
[18] Sandra K. Wittmann,et al. N-Benzylbenzamides: A Novel Merged Scaffold for Orally Available Dual Soluble Epoxide Hydrolase/Peroxisome Proliferator-Activated Receptor γ Modulators. , 2016, Journal of medicinal chemistry.
[19] R. Keith,et al. Evolution of a series of peptidoleukotriene antagonists: synthesis and structure/activity relationships of 1,3,5-substituted indoles and indazoles. , 1990, Journal of medicinal chemistry.
[20] B. E. Evans,et al. Methods for drug discovery: development of potent, selective, orally effective cholecystokinin antagonists. , 1988, Journal of medicinal chemistry.
[21] D. Huryn,et al. Structure Property Relationships of Carboxylic Acid Isosteres , 2016, Journal of medicinal chemistry.
[22] G. Schneider,et al. Rational design of a pirinixic acid derivative that acts as subtype-selective PPARgamma modulator. , 2010, Bioorganic & medicinal chemistry letters.
[23] J. Imig. Epoxyeicosatrienoic Acids and 20-Hydroxyeicosatetraenoic Acid on Endothelial and Vascular Function. , 2016, Advances in pharmacology.
[24] Sandra K. Wittmann,et al. Thermodynamic properties of leukotriene A4 hydrolase inhibitors. , 2016, Bioorganic & medicinal chemistry.
[25] M. Malkowski,et al. Investigating Substrate Promiscuity in Cyclooxygenase-2 , 2012, The Journal of Biological Chemistry.
[26] C. Nunes,et al. Biophysics in cancer: The relevance of drug-membrane interaction studies. , 2016, Biochimica et biophysica acta.
[27] N. Barnes,et al. Pranlukast, a novel leukotriene receptor antagonist: results of the first European, placebo controlled, multicentre clinical study in asthma. , 1997, Thorax.
[28] R. Krell,et al. Synthesis and pharmacological characterization of a series of leukotriene analogues with antagonist and agonist activities. , 1988, Journal of medicinal chemistry.
[29] Tomohiko Yamaguchi,et al. Identification of N-ethylmethylamine as a novel scaffold for inhibitors of soluble epoxide hydrolase by crystallographic fragment screening. , 2015, Bioorganic & medicinal chemistry.
[30] M. Toda,et al. New potent antagonists of leukotrienes C4 and D4. 1. Synthesis and structure-activity relationships. , 1988, Journal of medicinal chemistry.
[31] G. Schneider,et al. Nonacidic inhibitors of human microsomal prostaglandin synthase 1 (mPGES 1) identified by a multistep virtual screening protocol. , 2010, Journal of medicinal chemistry.
[32] John P. Overington,et al. ChEMBL: a large-scale bioactivity database for drug discovery , 2011, Nucleic Acids Res..
[33] S. Laufer. Discovery and development of ML3000 , 2001, InflammoPharmacology.
[34] Christopher W Murray,et al. Fragment-based lead discovery: leads by design. , 2005, Drug discovery today.
[35] G. Schneider,et al. Extending the structure-activity relationship of anthranilic acid derivatives as farnesoid X receptor modulators: development of a highly potent partial farnesoid X receptor agonist. , 2014, Journal of medicinal chemistry.
[36] B D Hammock,et al. Rationally designed multitarget agents against inflammation and pain. , 2013, Current medicinal chemistry.
[37] A. Paradiso,et al. Synthesis, characterization and biological evaluation of ureidofibrate-like derivatives endowed with peroxisome proliferator-activated receptor activity. , 2012, Journal of medicinal chemistry.
[38] Isabelle Krimm,et al. Ligand specificity, privileged substructures and protein druggability from fragment-based screening. , 2011, Current opinion in chemical biology.
[39] H. Pajouhesh,et al. Medicinal chemical properties of successful central nervous system drugs , 2005, NeuroRX.
[40] B. Persson,et al. Common structural features of mapeg—a widespread superfamily of membrane associated proteins with highly divergent functions in eicosanoid and glutathione metabolism , 2008, Protein science : a publication of the Protein Society.
[41] O. Hucke,et al. Development of Specific “Drug‐Like Property” Rules for Carboxylate‐Containing Oral Drug Candidates , 2010, ChemMedChem.
[42] Eliezer J Barreiro,et al. Privileged structures: a useful concept for the rational design of new lead drug candidates. , 2007, Mini reviews in medicinal chemistry.
[43] A. Sala,et al. Autocrine activity of cysteinyl leukotrienes in human vascular endothelial cells: Signaling through the CysLT₂ receptor. , 2015, Prostaglandins & other lipid mediators.
[44] D. Greaves,et al. Synthetic chemerin-derived peptides suppress inflammation through ChemR23 , 2008, The Journal of experimental medicine.
[45] Carlo Ballatore,et al. Carboxylic Acid (Bio)Isosteres in Drug Design , 2013, ChemMedChem.
[46] S. Curry,et al. Structural basis of the drug-binding specificity of human serum albumin. , 2005, Journal of molecular biology.
[47] Jilly F. Evans,et al. Update on leukotriene, lipoxin and oxoeicosanoid receptors: IUPHAR Review 7 , 2014, British journal of pharmacology.
[48] Andriy Kovalenko,et al. Calculation of local water densities in biological systems: a comparison of molecular dynamics simulations and the 3D-RISM-KH molecular theory of solvation. , 2011, The journal of physical chemistry. B.
[49] Hoa Le,et al. Comparison of metabolic soft spot predictions of CYP3A4, CYP2C9 and CYP2D6 substrates using MetaSite and StarDrop. , 2011, Combinatorial chemistry & high throughput screening.
[50] H. Aishita,et al. In vitro antagonism of ONO-1078, a newly developed anti-asthma agent, against peptide leukotrienes in isolated guinea pig tissues. , 1992, Japanese journal of pharmacology.
[51] N. Meanwell. Improving drug candidates by design: a focus on physicochemical properties as a means of improving compound disposition and safety. , 2011, Chemical research in toxicology.
[52] O. Civelli,et al. Molecular cloning and characterization of a second human cysteinyl leukotriene receptor: discovery of a subtype selective agonist. , 2000, Molecular pharmacology.
[53] A. Ichimura,et al. Nutritional Signaling via Free Fatty Acid Receptors , 2016, International journal of molecular sciences.
[54] L. Roncucci,et al. Chemerin/chemR23 axis in inflammation onset and resolution , 2014, Inflammation Research.
[55] G. Thatcher,et al. Rexinoids as Therapeutics for Alzheimer's Disease: Role of APOE. , 2017, Current topics in medicinal chemistry.
[56] D. Bernlohr,et al. Fatty acid binding proteins stabilize leukotriene A4: competition with arachidonic acid but not other lipoxygenase products. , 2004, Journal of lipid research.
[57] J. Evans,et al. Pharmacology of montelukast sodium (Singulair), a potent and selective leukotriene D4 receptor antagonist. , 1995, Canadian journal of physiology and pharmacology.
[58] E. Barreiro,et al. From nature to drug discovery: the indole scaffold as a 'privileged structure'. , 2009, Mini reviews in medicinal chemistry.
[59] R. Krell,et al. A novel series of selective leukotriene antagonists: exploration and optimization of the acidic region in 1,6-disubstituted indoles and indazoles. , 1990, Journal of medicinal chemistry.
[60] Jürgen Bajorath,et al. Integration of virtual and high-throughput screening , 2002, Nature Reviews Drug Discovery.
[61] C. Koboldt,et al. N-[[(5-methyl-3-phenylisoxazol-4-yl)-phenyl]sulfonyl]propanamide, sodium salt, parecoxib sodium: A potent and selective inhibitor of COX-2 for parenteral administration. , 2000, Journal of medicinal chemistry.
[62] Jingwei Shao,et al. Drug enterohepatic circulation and disposition: constituents of systems pharmacokinetics. , 2014, Drug discovery today.
[63] T. Willson,et al. 6alpha-ethyl-chenodeoxycholic acid (6-ECDCA), a potent and selective FXR agonist endowed with anticholestatic activity. , 2002, Journal of medicinal chemistry.
[64] M. Schubert-Zsilavecz,et al. Molecular determinants for improved activity at PPARα: structure-activity relationship of pirinixic acid derivatives, docking study and site-directed mutagenesis of PPARα. , 2014, Bioorganic & medicinal chemistry letters.
[65] M. Schubert-Zsilavecz,et al. Novel prostaglandin receptor modulators: a patent review (2002 – 2012) – part I: non-EP receptor modulators , 2013, Expert opinion on therapeutic patents.
[66] Yanping Xu. Recent Progress on Bile Acid Receptor Modulators for Treatment of Metabolic Diseases. , 2016, Journal of medicinal chemistry.
[67] R. Murphy,et al. Biosynthesis and metabolism of leukotrienes. , 2007, The Biochemical journal.
[68] P. Jakobsson,et al. Characterization of a human and murine mPGES-1 inhibitor and comparison to mPGES-1 genetic deletion in mouse models of inflammation. , 2013, Prostaglandins & other lipid mediators.
[69] C. Serhan,et al. Resolvin D1 binds human phagocytes with evidence for proresolving receptors , 2010, Proceedings of the National Academy of Sciences.
[70] Paul D. Jones,et al. 1-(1-acetyl-piperidin-4-yl)-3-adamantan-1-yl-urea (AR9281) as a potent, selective, and orally available soluble epoxide hydrolase inhibitor with efficacy in rodent models of hypertension and dysglycemia. , 2011, Bioorganic & medicinal chemistry letters.
[71] Y. Yu,et al. Fragment-based discovery of novel and selective mPGES-1 inhibitors Part 1: identification of sulfonamido-1,2,3-triazole-4,5-dicarboxylic acid. , 2013, Bioorganic & medicinal chemistry letters.
[72] J. Peters. Polypharmacology - foe or friend? , 2013, Journal of medicinal chemistry.
[73] Jilly F. Evans,et al. Characterization of the human cysteinyl leukotriene CysLT1 receptor , 1999, Nature.
[74] J. Chambers,et al. Identification, molecular cloning, expression, and characterization of a cysteinyl leukotriene receptor. , 1999, Molecular pharmacology.
[75] O. Werz,et al. Pirinixic acid derivatives as novel dual inhibitors of microsomal prostaglandin E2 synthase-1 and 5-lipoxygenase. , 2008, Journal of medicinal chemistry.
[76] D. A. Walsh,et al. Antiinflammatory agents. 3. Synthesis and pharmacological evaluation of 2-amino-3-benzoylphenylacetic acid and analogues. , 1984, Journal of medicinal chemistry.
[77] M. Furuhashi,et al. Fatty acid-binding proteins: role in metabolic diseases and potential as drug targets , 2008, Nature Reviews Drug Discovery.
[78] J. A. Grant,et al. A fast method of molecular shape comparison: A simple application of a Gaussian description of molecular shape , 1996, J. Comput. Chem..
[79] Daniela Schuster,et al. Discovery of New Liver X Receptor Agonists by Pharmacophore Modeling and Shape-Based Virtual Screening , 2014, J. Chem. Inf. Model..
[80] H. Edelsbrunner,et al. Anatomy of protein pockets and cavities: Measurement of binding site geometry and implications for ligand design , 1998, Protein science : a publication of the Protein Society.
[81] P. Young,et al. The discovery and development of zileuton: an orally active 5-lipoxygenase inhibitor. , 1992, International journal of immunopharmacology.
[82] A. Stalder,et al. Biomarker‐guided clinical development of the first‐in‐class anti‐inflammatory FPR2/ALX agonist ACT‐389949 , 2017, British journal of clinical pharmacology.
[83] D. Serra,et al. Fatty acid metabolism and the basis of brown adipose tissue function , 2015, Adipocyte.
[84] J. Crowet,et al. Complementary biophysical tools to investigate lipid specificity in the interaction between bioactive molecules and the plasma membrane: A review. , 2014, Biochimica et biophysica acta.
[85] F. Kuipers,et al. Beyond intestinal soap—bile acids in metabolic control , 2014, Nature Reviews Endocrinology.
[86] Petra Schneider,et al. Virtual Screening for PPAR Modulators Using a Probabilistic Neural Network , 2006, ChemMedChem.
[87] M. Romano,et al. Lipoxins and aspirin-triggered lipoxins in resolution of inflammation. , 2015, European journal of pharmacology.
[88] J. Rokach,et al. Biosynthesis, biological effects, and receptors of hydroxyeicosatetraenoic acids (HETEs) and oxoeicosatetraenoic acids (oxo-ETEs) derived from arachidonic acid. , 2015, Biochimica et biophysica acta.
[89] Ruili Huang,et al. Identification of Clinically Used Drugs That Activate Pregnane X Receptors , 2011, Drug Metabolism and Disposition.
[90] B. Levy,et al. Lipid mediators in the resolution of inflammation. , 2015, Cold Spring Harbor perspectives in biology.
[91] Gisbert Schneider,et al. Shapelets: Possibilities and limitations of shape‐based virtual screening , 2008, J. Comput. Chem..
[92] C. Andrade,et al. QSAR and QM/MM approaches applied to drug metabolism prediction. , 2012, Mini reviews in medicinal chemistry.
[93] M. Lehr,et al. Pyrrole alkanoic acid derivatives as nuisance inhibitors of microsomal prostaglandin E2 synthase-1. , 2012, European journal of medicinal chemistry.
[94] A. Gaggar,et al. A Critical Role for LTA4H in Limiting Chronic Pulmonary Neutrophilic Inflammation , 2010, Science.
[95] Christian Wolfrum,et al. Fatty acids and hypolipidemic drugs regulate peroxisome proliferator-activated receptors α- and γ-mediated gene expression via liver fatty acid binding protein: A signaling path to the nucleus , 2001, Proceedings of the National Academy of Sciences of the United States of America.
[96] Chang-Guo Zhan,et al. Novel human mPGES-1 inhibitors identified through structure-based virtual screening. , 2011, Bioorganic & medicinal chemistry.
[97] Fung Wp,et al. Effects of some naturally occurring prostaglandins and synthetic analogues on gastric secretion and ulcer healing in man. , 1976 .
[98] W Patrick Walters,et al. Acidic and basic drugs in medicinal chemistry: a perspective. , 2014, Journal of medicinal chemistry.
[99] Harren Jhoti,et al. The 'rule of three' for fragment-based drug discovery: where are we now? , 2013, Nature Reviews Drug Discovery.
[100] Camille G Wermuth,et al. Selective optimization of side activities: the SOSA approach. , 2006, Drug discovery today.
[101] R. Krell,et al. Biochemical and Pharmacological Characterization of the Binding of the Selective Peptide‐Leukotriene Antagonist, 3H‐ICI 198,615, to Leukotriene D4 Receptors in Guinea‐Pig Lung Membranes , 1988, Annals of the New York Academy of Sciences.
[102] J C Sacchettini,et al. Crystal structure of rat intestinal fatty-acid-binding protein. Refinement and analysis of the Escherichia coli-derived protein with bound palmitate. , 1989, Journal of molecular biology.
[103] A. A. Santilli,et al. A potent antihypercholesterolemic agent: [4-chloro-6-(2,3-xylidino)-2-pyrimidinylthio]acetic acid (Wy-14643) , 1974, Experientia.
[104] Dennis A. Smith. Metabolism, pharmacokinetics and toxicity of functional groups : impact of chemical building blocks on ADMET , 2010 .
[105] Xiaofeng Cui,et al. Free fatty acids-sensing G protein-coupled receptors in drug targeting and therapeutics. , 2013, Current medicinal chemistry.
[106] J B Farmer,et al. Selective inhibitor of slow reacting substance of anaphylaxis. , 1973, Nature: New biology.
[107] Karl Edman,et al. Novel prostaglandin D synthase inhibitors generated by fragment-based drug design. , 2008, Journal of medicinal chemistry.
[108] S. Wright,et al. Polyunsaturated fatty acids are FXR ligands and differentially regulate expression of FXR targets. , 2004, DNA and cell biology.
[109] Petra Schneider,et al. Scaffold‐Hopping Cascade Yields Potent Inhibitors of 5‐Lipoxygenase , 2008, ChemMedChem.
[110] J. Yanni,et al. Nepafenac, a Unique Nonsteroidal Prodrug with Potential Utility in the Treatment of Trauma-Induced Ocular Inflammation: I. Assessment of Anti-Inflammatory Efficacy , 2000, Inflammation.
[111] J. Wielens,et al. The Interaction of Lipophilic Drugs with Intestinal Fatty Acid-binding Protein* , 2005, Journal of Biological Chemistry.
[112] A. Lavecchia,et al. New 2-(aryloxy)-3-phenylpropanoic acids as peroxisome proliferator-activated receptor α/γ dual agonists able to upregulate mitochondrial carnitine shuttle system gene expression. , 2013, Journal of medicinal chemistry.
[113] G. Keserű,et al. Is there a link between selectivity and binding thermodynamics profiles? , 2015, Drug discovery today.
[114] N. Meanwell. Synopsis of some recent tactical application of bioisosteres in drug design. , 2011, Journal of medicinal chemistry.
[115] M. Schubert-Zsilavecz,et al. Anthranilic acid derivatives as nuclear receptor modulators--development of novel PPAR selective and dual PPAR/FXR ligands. , 2015, Bioorganic & medicinal chemistry.
[116] J. Gordon,et al. Refined apoprotein structure of rat intestinal fatty acid binding protein produced in Escherichia coli. , 1989, Proceedings of the National Academy of Sciences of the United States of America.
[117] Björn Krüger,et al. The holistic integration of virtual screening in drug discovery. , 2013, Drug discovery today.
[118] Lucia Altucci,et al. Design of selective nuclear receptor modulators: RAR and RXR as a case study , 2007, Nature Reviews Drug Discovery.
[119] Daniel M. Lowe,et al. ADMET rules of thumb II: A comparison of the effects of common substituents on a range of ADMET parameters. , 2009, Bioorganic & medicinal chemistry.
[120] Petra Schneider,et al. Revealing the macromolecular targets of complex natural products. , 2014, Nature chemistry.
[121] Thierry Langer,et al. Discovery of novel PPAR ligands by a virtual screening approach based on pharmacophore modeling, 3D shape, and electrostatic similarity screening. , 2008, Journal of medicinal chemistry.
[122] H. Tsuchiya. Membrane Interactions of Phytochemicals as Their Molecular Mechanism Applicable to the Discovery of Drug Leads from Plants , 2015, Molecules.
[123] K. Seong,et al. Psoralidin, a dual inhibitor of COX‐2 and 5‐LOX, regulates ionizing radiation (IR)‐induced pulmonary inflammation , 2011, Biochemical pharmacology.
[124] B. Gertz,et al. Pharmacokinetics, Bioavailability, and Safety of Montelukast Sodium (MK-0476) in Healthy Males and Females , 1996, Pharmaceutical Research.
[125] A. Holt,et al. On the disruption of biochemical and biological assays by chemicals leaching from disposable laboratory plasticware. , 2012, Canadian journal of physiology and pharmacology.
[126] J Zhang,et al. Effects of montelukast (MK-0476), a new potent cysteinyl leukotriene (LTD4) receptor antagonist, in patients with chronic asthma. , 1996, The Journal of allergy and clinical immunology.
[127] M. Lambert,et al. Substituted 2-[(4-aminomethyl)phenoxy]-2-methylpropionic acid PPARalpha agonists. 1. Discovery of a novel series of potent HDLc raising agents. , 2007, Journal of medicinal chemistry.
[128] G. Schneider,et al. The molecular mechanism of the inhibition by licofelone of the biosynthesis of 5‐lipoxygenase products , 2007, British journal of pharmacology.
[129] B. Staels,et al. Drug Insight: mechanisms of action and therapeutic applications for agonists of peroxisome proliferator-activated receptors , 2007, Nature Clinical Practice Endocrinology &Metabolism.
[130] A. D. de Lera,et al. An Endogenous Mammalian Retinoid X Receptor Ligand, At Last! , 2016, ChemMedChem.
[131] Daniel Moser,et al. Exploring the chemical space of multitarget ligands using aligned self-organizing maps. , 2013, ACS medicinal chemistry letters.
[132] R. Young,et al. The discovery of a new structural class of potent orally active leukotriene D4 antagonists , 1992 .
[133] Susanne Winiwarter,et al. Discovery of AZD6642, an inhibitor of 5-lipoxygenase activating protein (FLAP) for the treatment of inflammatory diseases. , 2015, Journal of medicinal chemistry.
[134] P. Leeson,et al. The influence of drug-like concepts on decision-making in medicinal chemistry , 2007, Nature Reviews Drug Discovery.
[135] S. Majumdar,et al. Role of metabolism in ocular drug delivery. , 2004, Current drug metabolism.
[136] D. Bojanic,et al. Impact of high-throughput screening in biomedical research , 2011, Nature Reviews Drug Discovery.
[137] Kam Y. J. Zhang,et al. A family of phosphodiesterase inhibitors discovered by cocrystallography and scaffold-based drug design , 2005, Nature Biotechnology.
[138] C. Serhan,et al. Resolvins and protectins in inflammation resolution. , 2011, Chemical reviews.
[139] A. Robert,et al. Inhibition of gastric secretion by prostaglandins , 1967, The American journal of digestive diseases.
[140] O. Werz,et al. Design and Development of Microsomal Prostaglandin E2 Synthase-1 Inhibitors: Challenges and Future Directions. , 2016, Journal of medicinal chemistry.
[141] B. Spiegelman,et al. International Union of Pharmacology. LXI. Peroxisome Proliferator-Activated Receptors , 2006, Pharmacological Reviews.
[142] M. Schubert-Zsilavecz,et al. Novel prostaglandin receptor modulators – Part II: EP receptor modulators; a patent review (2002 – 2012) , 2013, Expert opinion on therapeutic patents.
[143] Charles N. Serhan,et al. Resolvin E1 Selectively Interacts with Leukotriene B4 Receptor BLT1 and ChemR23 to Regulate Inflammation1 , 2007, The Journal of Immunology.
[144] Hilde Cheroutre,et al. Retinoic Acid and Retinoic Acid Receptors as Pleiotropic Modulators of the Immune System. , 2016, Annual review of immunology.
[145] Jilly F. Evans,et al. 5-Lipoxygenase-activating protein (FLAP) inhibitors. Part 4: development of 3-[3-tert-butylsulfanyl-1-[4-(6-ethoxypyridin-3-yl)benzyl]-5-(5-methylpyridin-2-ylmethoxy)-1H-indol-2-yl]-2,2-dimethylpropionic acid (AM803), a potent, oral, once daily FLAP inhibitor. , 2011, Journal of medicinal chemistry.
[146] Sander Kersten,et al. Roles of PPARs in health and disease , 2000, Nature.
[147] R. S. Rogers,et al. Synthesis and biological evaluation of the 1,5-diarylpyrazole class of cyclooxygenase-2 inhibitors: identification of 4-[5-(4-methylphenyl)-3-(trifluoromethyl)-1H-pyrazol-1-yl]benze nesulfonamide (SC-58635, celecoxib). , 1997, Journal of medicinal chemistry.
[148] D. Steinhilber,et al. Recent advances in the search for novel 5-lipoxygenase inhibitors. , 2014, Basic & clinical pharmacology & toxicology.
[149] K. Takano,et al. Estrogenic impurities in labware , 2001, Nature Biotechnology.
[150] R. Young,et al. Discovery of MK-0476, a potent and orally active leukotriene D4 receptor antagonist devoid of peroxisomal enxyme induction , 1995 .
[151] Ying Yu,et al. Discovery and optimization of 1,3,4-trisubstituted-pyrazolone derivatives as novel, potent, and nonsteroidal farnesoid X receptor (FXR) selective antagonists. , 2012, Journal of medicinal chemistry.
[152] Chris Oostenbrink,et al. Prediction of cytochrome P450 mediated metabolism. , 2015, Advanced drug delivery reviews.
[153] Y. Uto,et al. Recent progress in the discovery and development of stearoyl CoA desaturase inhibitors. , 2016, Chemistry and physics of lipids.
[154] C. Johansson,et al. Stimulation by intragastrically administered E2 prostaglandins of human gastric mucus output , 1979, European journal of clinical investigation.
[155] R. Parker,et al. Treatment of diabetes and atherosclerosis by inhibiting fatty-acid-binding protein aP2 , 2007, Nature.
[156] G. Bifulco,et al. Structure‐Based Design of Microsomal Prostaglandin E2 Synthase‐1 (mPGES‐1) Inhibitors using a Virtual Fragment Growing Optimization Scheme , 2016, ChemMedChem.
[157] R. Keith,et al. In vitro pharmacology of ICI 198,615: a novel, potent and selective peptide leukotriene antagonist. , 1987, The Journal of pharmacology and experimental therapeutics.
[158] Brian Pease,et al. Discovery of Leukotriene A4 Hydrolase Inhibitors Using Metabolomics Biased Fragment Crystallography† , 2009, Journal of medicinal chemistry.
[159] Gregor Eichele,et al. International Union of Pharmacology. LXIII. Retinoid X Receptors , 2006, Pharmacological Reviews.
[160] R. Desimone,et al. Privileged structures: applications in drug discovery. , 2004, Combinatorial chemistry & high throughput screening.
[161] Jilly F. Evans,et al. International Union of Basic and Clinical Pharmacology. LXXXIV: Leukotriene Receptor Nomenclature, Distribution, and Pathophysiological Functions , 2011, Pharmacological Reviews.
[162] P. Hajduk,et al. Privileged molecules for protein binding identified from NMR-based screening. , 2000, Journal of medicinal chemistry.
[163] James Ferguson,et al. Software automation tools for increased throughput metabolic soft-spot identification in early drug discovery. , 2013, Bioanalysis.
[164] Dieter Lang,et al. Predicting drug metabolism: experiment and/or computation? , 2015, Nature Reviews Drug Discovery.
[165] R. Obach,et al. Physicochemical determinants of human renal clearance. , 2009, Journal of medicinal chemistry.
[166] Tudor I. Oprea,et al. The significance of acid/base properties in drug discovery. , 2013, Chemical Society reviews.
[167] J. Bassaganya-Riera,et al. Virtual Screening as a Technique for PPAR Modulator Discovery , 2009, PPAR research.
[168] James R Kiefer,et al. The novel benzopyran class of selective cyclooxygenase-2 inhibitors. Part 2: the second clinical candidate having a shorter and favorable human half-life. , 2010, Bioorganic & medicinal chemistry letters.
[169] Leandro Martínez,et al. Medium Chain Fatty Acids Are Selective Peroxisome Proliferator Activated Receptor (PPAR) γ Activators and Pan-PPAR Partial Agonists , 2012, PloS one.
[170] D. Merk. Chances and challenges of retinoid X receptor gamma targeting for regenerative multiple sclerosis treatment. , 2015, Future medicinal chemistry.
[171] Gerhard Klebe,et al. Adding calorimetric data to decision making in lead discovery: a hot tip , 2010, Nature Reviews Drug Discovery.
[172] A. Harris,et al. Antiangiogenic and tumour inhibitory effects of downregulating tumour endothelial FABP4 , 2016, Oncogene.
[173] Daniel Moser,et al. Dual-target virtual screening by pharmacophore elucidation and molecular shape filtering. , 2012, ACS medicinal chemistry letters.
[174] L. Bito,et al. Phenyl-substituted prostaglandins: potent and selective antiglaucoma agents. , 1993, Journal of medicinal chemistry.
[175] Hannu Raunio,et al. Prodrugs—from Serendipity to Rational Design , 2011, Pharmacological Reviews.
[176] R. Murphy,et al. Leukotriene C: a slow-reacting substance from murine mastocytoma cells. , 1979, Proceedings of the National Academy of Sciences of the United States of America.
[177] Brian K Shoichet,et al. A detergent-based assay for the detection of promiscuous inhibitors , 2006, Nature Protocols.
[178] Y. Urade,et al. Enzymes of the cyclooxygenase pathways of prostanoid biosynthesis. , 2011, Chemical reviews.
[179] R Scott Obach,et al. Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination. , 2010, Journal of medicinal chemistry.
[180] Bengt Samuelsson,et al. Binding of Pro-Gly-Pro at the active site of leukotriene A4 hydrolase/aminopeptidase and development of an epoxide hydrolase selective inhibitor , 2014, Proceedings of the National Academy of Sciences.
[181] T. Maduskuie,et al. Hydroxyacetophenone-derived antagonists of the peptidoleukotrienes. , 1989, Journal of Medicinal Chemistry.
[182] T. Velkov. Thermodynamics of lipophilic drug binding to intestinal fatty acid binding protein and permeation across membranes. , 2009, Molecular pharmaceutics.
[183] D. Brocks,et al. Evening dosing is associated with higher plasma concentrations of pranlukast, a leukotriene receptor antagonist, in healthy male volunteers. , 2003, British Journal of Clinical Pharmacology.
[184] O. Werz,et al. Pirinixic acids: flexible fatty acid mimetics with various biological activities. , 2015, Future medicinal chemistry.
[185] R. Morphy,et al. Designed multiple ligands. An emerging drug discovery paradigm. , 2005, Journal of medicinal chemistry.
[186] Weihua Li,et al. Discovery of new non-steroidal FXR ligands via a virtual screening workflow based on Phase shape and induced fit docking. , 2012, Bioorganic & medicinal chemistry letters.
[187] Kazuya Maeda,et al. Clinical significance of organic anion transporting polypeptides (OATPs) in drug disposition: their roles in hepatic clearance and intestinal absorption. , 2013, Biopharmaceutics & drug disposition.
[188] T. Hori,et al. Crystal structure of anti-configuration of indomethacin and leukotriene B4 12-hydroxydehydrogenase/15-oxo-prostaglandin 13-reductase complex reveals the structural basis of broad spectrum indomethacin efficacy. , 2006, Journal of biochemistry.
[189] Manfred Schubert-Zsilavecz,et al. Medicinal chemistry of farnesoid X receptor ligands: from agonists and antagonists to modulators. , 2012, Future medicinal chemistry.
[190] S. Narumiya,et al. International Union of Basic and Clinical Pharmacology. LXXXIII: Classification of Prostanoid Receptors, Updating 15 Years of Progress , 2011, Pharmacological Reviews.
[191] M. Schubert-Zsilavecz,et al. Therapeutic modulators of peroxisome proliferator-activated receptors (PPAR): a patent review (2008–present) , 2012, Expert opinion on therapeutic patents.
[192] B. Shoichet,et al. High-throughput assays for promiscuous inhibitors , 2005, Nature chemical biology.
[193] Sanjay S. Patel,et al. Latanoprost. A review of its pharmacological properties, clinical efficacy and tolerability in the management of primary open-angle glaucoma and ocular hypertension. , 1996, Drugs & aging.
[194] Thomas Mendgen,et al. Privileged scaffolds or promiscuous binders: a comparative study on rhodanines and related heterocycles in medicinal chemistry. , 2012, Journal of medicinal chemistry.
[195] E. Freire. Do enthalpy and entropy distinguish first in class from best in class? , 2008, Drug discovery today.
[196] G. Schneider,et al. Revealing the Macromolecular Targets of Fragment-Like Natural Products. , 2015, Angewandte Chemie.
[197] Wolfgang Albrecht,et al. Licofelone Suppresses Prostaglandin E2 Formation by Interference with the Inducible Microsomal Prostaglandin E2 Synthase-1 , 2008, Journal of Pharmacology and Experimental Therapeutics.
[198] A. Wolkoff. Organic anion uptake by hepatocytes. , 2014, Comprehensive Physiology.
[199] Sridhar Duvvuri,et al. Drug delivery to the retina: challenges and opportunities , 2003, Expert opinion on biological therapy.
[200] Bernard Faller,et al. Metabolic soft spot identification and compound optimization in early discovery phases using MetaSite and LC-MS/MS validation. , 2009, Journal of medicinal chemistry.
[201] I. Lu,et al. Structure-based drug design of a novel family of PPARgamma partial agonists: virtual screening, X-ray crystallography, and in vitro/in vivo biological activities. , 2006, Journal of medicinal chemistry.
[202] M. Dawson,et al. The retinoid X receptors and their ligands. , 2012, Biochimica et biophysica acta.
[203] D. Steinhilber,et al. Inhibitors of the arachidonic acid cascade: interfering with multiple pathways. , 2014, Basic & clinical pharmacology & toxicology.
[204] K. Maeda. Organic anion transporting polypeptide (OATP)1B1 and OATP1B3 as important regulators of the pharmacokinetics of substrate drugs. , 2015, Biological & pharmaceutical bulletin.
[205] Dora M Schnur,et al. Are target-family-privileged substructures truly privileged? , 2006, Journal of medicinal chemistry.
[206] Jan M. Kriegl,et al. From Molecular Shape to Potent Bioactive Agents I: Bioisosteric Replacement of Molecular Fragments , 2009, ChemMedChem.
[207] A. Brash,et al. The Structure of Human 5-Lipoxygenase , 2011, Science.
[208] Simona Distinto,et al. How To Optimize Shape-Based Virtual Screening: Choosing the Right Query and Including Chemical Information , 2009, J. Chem. Inf. Model..
[209] M. Gleeson. Generation of a set of simple, interpretable ADMET rules of thumb. , 2008, Journal of medicinal chemistry.
[210] Takao Shimizu,et al. The Lipoxin Receptor ALX: Potent Ligand-Specific and Stereoselective Actions in Vivo , 2006, Pharmacological Reviews.
[211] John P. Overington,et al. Can we rationally design promiscuous drugs? , 2006, Current opinion in structural biology.
[212] Hans-Joachim Böhm,et al. A guide to drug discovery: Hit and lead generation: beyond high-throughput screening , 2003, Nature Reviews Drug Discovery.
[213] S. Hwang,et al. Sorafenib has soluble epoxide hydrolase inhibitory activity, which contributes to its effect profile in vivo , 2009, Molecular Cancer Therapeutics.
[214] Bernstein. Chemistry and structure-activity relationships of leukotriene receptor antagonists , 1998, American journal of respiratory and critical care medicine.
[215] G. Schneider,et al. From Molecular Shape to Potent Bioactive Agents II: Fragment‐Based de novo Design , 2009, ChemMedChem.
[216] D. Steinhilber,et al. Small molecules with anti-inflammatory properties in clinical development. , 2016, Pharmacology & therapeutics.
[217] Joseph Cheriyan,et al. Pharmacokinetics, pharmacodynamics and adverse event profile of GSK2256294, a novel soluble epoxide hydrolase inhibitor. , 2016, British journal of clinical pharmacology.
[218] J. D. Clark,et al. Thermodynamic characterization of cytosolic phospholipase A2 alpha inhibitors. , 2008, Analytical biochemistry.
[219] A. K. Willard,et al. Chemically stable homocinnamyl analogues of the leukotrienes: synthesis and preliminary biological evaluation. , 1986, Journal of medicinal chemistry.
[220] D. Steinhilber,et al. Cysteinyl leukotriene-receptor-1 antagonists interfere with PGE2 synthesis by inhibiting mPGES-1 activity. , 2013, Biochemical pharmacology.
[221] B. Hudson,et al. Discovery of TUG-770: A Highly Potent Free Fatty Acid Receptor 1 (FFA1/GPR40) Agonist for Treatment of Type 2 Diabetes , 2013, ACS medicinal chemistry letters.
[222] E. Barreiro,et al. The methylation effect in medicinal chemistry. , 2011, Chemical reviews.
[223] R. Thandavarayan,et al. Targeting fatty acid metabolism in heart failure: is it a suitable therapeutic approach? , 2016, Drug discovery today.
[224] J. Lehmann,et al. Peroxisome Proliferator-activated Receptors α and γ Are Activated by Indomethacin and Other Non-steroidal Anti-inflammatory Drugs* , 1997, The Journal of Biological Chemistry.
[225] A. Brash,et al. Conversion of human 5‐lipoxygenase to a 15‐lipoxygenase by a point mutation to mimic phosphorylation at Serine‐663 , 2012 .
[226] A. Kay,et al. Inhibition of eosinophil chemotaxis by the antagonist of slow reacting substance of anaphylaxis—compound FPL 55712 * , 1974, The Journal of pharmacy and pharmacology.
[227] C. Murray,et al. The rise of fragment-based drug discovery. , 2009, Nature chemistry.
[228] Daniela Schuster,et al. Pharmacophore-based discovery of FXR agonists. Part I: Model development and experimental validation , 2011, Bioorganic & medicinal chemistry.
[229] D. A. Walsh,et al. Antiinflammatory agents. 4. Syntheses and biological evaluation of potential prodrugs of 2-amino-3-benzoylbenzeneacetic acid and 2-amino-3-(4-chlorobenzoyl)benzeneacetic acid. , 1990, Journal of medicinal chemistry.
[230] Tomohiko Yamaguchi,et al. Structural insights into binding of inhibitors to soluble epoxide hydrolase gained by fragment screening and X-ray crystallography. , 2014, Bioorganic & medicinal chemistry.
[231] F. Hart,et al. Indomethacin: A New Non-steroid Anti-inflammatory Agent , 1963, British medical journal.
[232] Richard Morphy,et al. The physicochemical challenges of designing multiple ligands. , 2006, Journal of medicinal chemistry.
[233] R. Glazer,et al. Induction of Metastatic Gastric Cancer by Peroxisome Proliferator-Activated Receptorδ Activation , 2010, PPAR research.
[234] Wenlian Zhang,et al. Identification of the Orphan G Protein-coupled Receptor GPR31 as a Receptor for 12-(S)-Hydroxyeicosatetraenoic Acid* , 2011, The Journal of Biological Chemistry.